Overview

To Assess the Efficacy of Early Introduction of a Combination of Low Dose Vasopressin Analogue in Addition to Noradrenaline as a Vasopressor in Patients of Cirrhosis With Septic Shock

Status:
Completed
Trial end date:
2017-05-31
Target enrollment:
0
Participant gender:
All
Summary
The consecutive patients admitted to Intensive care unit of Hepatology department of ILBS and full filling all the eligibility criteria will be enrolled in 1:1 ration by the process of randomization.- The study is an open level study. The investigators will strictly follow the randomization table to give therapy as per the intervention arm. - Intervention:-the therapeutic intervention is vasopressor i.e. noradrenaline alone and terlipressin along with noradrenaline to maintain the MAP >65mm Hg. - Intervention arm - Arm (A) - Noradrenaline - Arm (B) - Noradrenaline + low dose terlipressin
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Treatments:
Arginine Vasopressin
Lypressin
Norepinephrine
Terlipressin
Vasoconstrictor Agents
Vasopressins
Criteria
Inclusion Criteria:

- 18-70 yr

- Cirrhosis with septic shock not responding to fluid resuscitation within 2 hrs.

Exclusion Criteria:

- ECG (ElectroCardiography)changes at presentation which exclude the use of vasopressin
analouges

- Cardiac dysfunction ( valvular heart disease, coronary artery disease)

- Acute mesenteric ischemia (confirmed or suspected) or vasospastic diathesis (e.g.
Reynaud's syndrome or related diseases).

- Pregnancy

- Acute GI bleed

- No Consent